

Michael J Wagner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2755774/publications.pdf>

Version: 2024-02-01

35
papers

1,173
citations

623734

14
h-index

501196

28
g-index

35
all docs

35
docs citations

35
times ranked

1718
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk assessment in solitary fibrous tumors: validation and refinement of a risk stratification model. <i>Modern Pathology</i> , 2017, 30, 1433-1442.	5.5	261
2	A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma. <i>Sarcoma</i> , 2013, 2013, 1-8.	1.3	151
3	Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA). <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1114-1123.	4.1	94
4	Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma. <i>JAMA Oncology</i> , 2020, 6, 1778.	7.1	66
5	Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART). , 2021, 9, e002990.		58
6	<i><sc>TERT</sc></i> promoter mutations in solitary fibrous tumour. <i>Histopathology</i> , 2018, 73, 843-851.	2.9	47
7	Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine. <i>Oncotarget</i> , 2015, 6, 40642-40654.	1.8	45
8	Chemotherapy for Bone Sarcoma in Adults. <i>Journal of Oncology Practice</i> , 2016, 12, 208-216.	2.5	44
9	Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2894-2904.	4.1	37
10	Propranolol for the treatment of vascular sarcomas. <i>Journal of Experimental Pharmacology</i> , 2018, Volume 10, 51-58.	3.2	31
11	Angiosarcoma heterogeneity and potential therapeutic vulnerability to immune checkpoint blockade: insights from genomic sequencing. <i>Genome Medicine</i> , 2020, 12, 61.	8.2	31
12	Endothelial cell malignancies: new insights from the laboratory and clinic. <i>Npj Precision Oncology</i> , 2017, 1, 11.	5.4	27
13	Synovial Sarcoma of the Head and Neck: A Single Institution Review. <i>Sarcoma</i> , 2017, 2017, 1-8.	1.3	27
14	Response to PD1 inhibition in conventional chondrosarcoma. , 2018, 6, 94.		26
15	A retrospective chart review of drug treatment patterns and clinical outcomes among patients with metastatic or recurrent soft tissue sarcoma refractory to one or more prior chemotherapy treatments. <i>BMC Cancer</i> , 2015, 15, 175.	2.6	24
16	CD4+ T cell and M2 macrophage infiltration predict dedifferentiated liposarcoma patient outcomes. , 2021, 9, e002812.		21
17	Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults. <i>Oncologist</i> , 2017, 22, 1271-1277.	3.7	20
18	Neoadjuvant Therapy Induces a Potent Immune Response to Sarcoma, Dominated by Myeloid and B Cells. <i>Clinical Cancer Research</i> , 2022, 28, 1701-1711.	7.0	17

#	ARTICLE	IF	CITATIONS
19	A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma. <i>Clinical Cancer Research</i> , 2022, 28, 2306-2312.	7.0	17
20	Targeting cancer testis antigens in synovial sarcoma. , 2021, 9, e002072.		16
21	Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients. <i>Scientific Reports</i> , 2017, 7, 9519.	3.3	15
22	Combined VEGFR and MAPK pathway inhibition in angiosarcoma. <i>Scientific Reports</i> , 2021, 11, 9362.	3.3	14
23	Is Chemotherapy Associated with Improved Overall Survival in Patients with Dedifferentiated Chondrosarcoma? A SEER Database Analysis. <i>Clinical Orthopaedics and Related Research</i> , 2022, 480, 748-758.	1.5	14
24	Chemotherapy for Bone Sarcomas in Adults: The MD Anderson Experience. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e656-e660.	3.8	13
25	Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. <i>Scientific Reports</i> , 2016, 6, 35448.	3.3	12
26	Evaluating the Soft Tissue Sarcoma Paradigm for the Local Management of Extraskelatal Ewing Sarcoma. <i>Oncologist</i> , 2021, 26, 250-260.	3.7	9
27	Point-of-Care Ultrasound Applications in the Outpatient Clinic. <i>Southern Medical Journal</i> , 2018, 111, 404-410.	0.7	9
28	Long-term Outcomes for Extraskelatal Myxoid Chondrosarcoma: A SEER Database Analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2351-2357.	2.5	8
29	An Unusual Case of Central Retinal Vein Occlusion and Review of the Toxicity Profile of Regorafenib in GIST Patients. <i>Current Oncology Reports</i> , 2016, 18, 49.	4.0	5
30	Immunologic Gene Signature Analysis Correlates Myeloid Cells and M2 Macrophages with Time to Trabectedin Failure in Sarcoma Patients. <i>Cancers</i> , 2022, 14, 1290.	3.7	5
31	Doxorubicin and Olaratumab Versus Doxorubicin, Ifosfamide, and Mesna for Treatment of Advanced Soft Tissue Sarcomas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 446-451.	1.3	4
32	Outcomes of Patients with Sarcoma and COVID-19 Infection: A Single Institution Cohort Analysis. <i>Cancer Investigation</i> , 2021, 39, 1-6.	1.3	4
33	Sarcoma Care Collaborations: Models for patient centered sub-specialty oncology care in the COVID-19 era and beyond. <i>International Journal of Cancer Care and Delivery</i> , 0, , .	0.0	1
34	Combination Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma—Reply. <i>JAMA Oncology</i> , 2021, 7, 465.	7.1	0
35	Impact of nodal involvement on survival outcomes in chondrosarcoma: retrospective cohort analysis of Surveillance, Epidemiology, and End Results (SEER) database (2004–2015). <i>International Journal of Surgery Oncology</i> , 2021, 5, 91.	0.2	0